ARIAD Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 1991, the company has made significant strides in developing innovative therapies for cancer, particularly in the field of targeted treatments. ARIAD is renowned for its core product, Iclusig (ponatinib), which addresses specific genetic mutations in leukaemia, setting it apart in a competitive market. With a strong focus on oncology, ARIAD has established itself as a leader in precision medicine, contributing to advancements in patient care. The company’s commitment to research and development has led to notable achievements, including collaborations with major healthcare institutions. As ARIAD continues to expand its operational reach, it remains dedicated to transforming cancer treatment and improving patient outcomes globally.
We don't have data for ARIAD Pharmaceuticals, Inc., but we can show you information about their parent organization instead.
View parent company